Avantor (NYSE:AVTR) Given New $27.00 Price Target at Evercore ISI

Avantor (NYSE:AVTR) had its price objective decreased by Evercore ISI from $28.00 to $27.00 in a report issued on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Evercore ISI’s target price would suggest a potential upside of 30.94% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft increased their price target on Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Thursday, April 18th. Robert W. Baird lowered their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, April 29th. Finally, Barclays dropped their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Avantor currently has an average rating of “Moderate Buy” and a consensus target price of $26.29.

Avantor Stock Performance

AVTR stock traded down $0.15 on Tuesday, hitting $20.62. The company’s stock had a trading volume of 1,061,083 shares, compared to its average volume of 5,789,071. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94. The stock has a market cap of $14.01 billion, a price-to-earnings ratio of 52.90, a price-to-earnings-growth ratio of 2.15 and a beta of 1.32. Avantor has a 1 year low of $16.63 and a 1 year high of $26.16. The firm has a 50 day moving average of $23.73 and a two-hundred day moving average of $23.82.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. The firm had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.68 billion. Avantor had a return on equity of 13.01% and a net margin of 3.79%. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. Equities analysts predict that Avantor will post 1.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Mariner LLC lifted its stake in Avantor by 17.3% in the 3rd quarter. Mariner LLC now owns 42,025 shares of the company’s stock valued at $886,000 after buying an additional 6,196 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Avantor by 170.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 24,722 shares of the company’s stock worth $521,000 after purchasing an additional 15,580 shares in the last quarter. Bank of Nova Scotia raised its stake in Avantor by 18.1% in the 3rd quarter. Bank of Nova Scotia now owns 16,024 shares of the company’s stock valued at $338,000 after purchasing an additional 2,455 shares during the last quarter. Glenmede Trust Co. NA lifted its holdings in Avantor by 300.1% in the 3rd quarter. Glenmede Trust Co. NA now owns 139,143 shares of the company’s stock valued at $2,933,000 after purchasing an additional 104,362 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Avantor in the 3rd quarter valued at about $16,864,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.